Ferroptosis In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Ferroptosis is an iron-dependent, non-apoptotic form of programmed cell death characterized by the accumulation of lipid peroxides. Originally described in 2012, ferroptosis has emerged as a critical mechanism in neurodegeneration, with increasing evidence pointing to its role in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative conditions.
Unlike apoptosis, ferroptosis is distinguished by:
- Iron dependency (Fe²⁺ accumulation)
- Glutathione depletion
- Lipid peroxidation accumulation
- Absence of caspase activation
- Morphological features including shrunken mitochondria with condensed membranes
This pathway is closely related to lipid peroxidation, iron dysregulation, and oxidative stress in neurodegeneration.
flowchart TD
A[System Xc⁻ Inhibition] --> B[Glutathione Depletion]
B --> C[GPX4 Inactivation]
C --> D[Lipid Peroxide Accumulation]
E[Iron Overload] --> F[Fenton Reactions]
F --> D
D --> G[Membrane Damage]
G --> H[Cell Death]
I[Ferritinophagy] --> E
J[NCOA4] --> I
K[Iron Response] --> E
The system Xc⁻ cystine/glutamate antiporter is a heterodimer composed of SLC7A11 and SLC3A2 subunits. Its function:
- Imports cystine: Exchanges extracellular cystine for intracellular glutamate
- Maintains glutathione synthesis: Cystine is reduced to cysteine for GSH production
- Antioxidant defense: GSH serves as cofactor for glutathione peroxidase 4 (GPX4)
Inhibition triggers ferroptosis when:
- System Xc⁻ is inhibited (e.g., erastin, sulfasalazine)
- Glutathione is depleted
- GPX4 is inactivated or downregulated
Glutathione peroxidase 4 (GPX4) is the key enzyme preventing ferroptosis:
- Function: Reduces lipid hydroperoxides to lipid alcohols
- Cofactor: Requires glutathione as electron donor
- Substrates: Phospholipid hydroperoxides (PLOOH)
- Isoforms: Cytosolic (cGPX4), mitochondrial (mGPX4), and nuclear (nGPX4)
GPX4 inhibition leads to:
- Accumulation of lipid peroxides
- Membrane damage
- Ferroptotic cell death
Iron is essential for ferroptosis through Fenton chemistry:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻ (Hydroxyl radical)
Fe²⁺ + LOOH → Fe³⁺ + LO• + OH⁻ (Lipid alkoxyl radical)
These reactive species attack membrane PUFAs, initiating lipid peroxidation chain reactions.
| Process |
Key Proteins |
Role in Ferroptosis |
| Iron import |
Transferrin receptor (TFRC), DMT1 |
Increases intracellular iron |
| Iron storage |
Ferritin (FTL, FTH1) |
Sequesters iron, inhibits ferroptosis |
| Iron export |
Ferroportin (FPN) |
Exports excess iron |
| Ferritinophagy |
NCOA4 |
Releases iron from ferritin |
| Iron regulation |
IREB2, IRP2 |
Post-transcriptional iron regulation |
NCOA4-mediated ferritinophagy is a selective autophagy process:
- Delivers ferritin to lysosomes
- Releases iron for ferroptosis
- Inhibited by NCOA4 knockdown (prevents ferroptosis)
Membrane PUFAs are primary targets for peroxidation:
- Key PUFAs: Arachidonic acid (AA), Adrenic acid (AdA), Docosahexaenoic acid (DHA)
- Location: Phosphatidylethanolamine (PE), phosphatidylcholine (PC)
- Enrichment: Neuronal membranes are highly enriched in PUFAs
ACSL4 is critical for ferroptosis:
- Activates long-chain PUFAs for membrane incorporation
- ACSL4 knockout confers ferroptosis resistance
- Regulates lipid composition for ferroptosis susceptibility
12/15-LOX promotes ferroptosis:
- Catalyzes PUFA peroxidation
- Works with GPX4 to regulate cell death
- LOX inhibitors can prevent ferroptosis
| Factor |
Mechanism |
| Erastin |
Inhibits System Xc⁻, depletes GSH |
| RSL3 |
Directly inhibits GPX4 |
| FIN56 |
Promotes GPX4 degradation |
| DHPs |
Erastin analogs with enhanced potency |
| p53 |
Can downregulate SLC7A11 transcription |
| Inhibitor |
Mechanism |
| Ferrostatin-1 |
Lipophilic antioxidant, scavenges lipid ROS |
| Liproxstatin-1 |
Inhibits lipid peroxidation |
| Deferoxamine (DFO) |
Iron chelator |
| Vitamin E |
Chain-breaking antioxidant |
| CoQ10 |
Antioxidant in membranes |
- Increased iron accumulation in AD brain regions
- Elevated lipid peroxidation markers (4-HNE, MDA)
- GPX4 downregulated in AD hippocampus
- Transferrin saturation increased in AD
- Amyloid-beta interaction: Aβ promotes iron dysregulation
- Tau pathology: Linked to iron accumulation
- Mitochondrial dysfunction: Increases ROS, promotes ferroptosis
- Neuroinflammation: Microglial iron release
- Iron chelators (deferoxamine, clioquinol)
- GPX4 activators
- Lipophilic antioxidants (ferrostatin analogs)
- NCOA4 inhibitors
- Iron accumulation in substantia nigra pars compacta
- Elevated lipid peroxidation in PD brains
- GPX4 activity reduced in PD
- System Xc⁻ dysfunction in PD models
- Nigral iron accumulation: Via transferrin receptor upregulation
- Dopamine oxidation: Creates quinones that promote Fenton chemistry
- Mitochondrial Complex I deficiency: Increases ROS
- α-Synuclein interaction: May promote ferritinophagy
- Iron chelation therapy
- GPX4-based interventions
- Combined antioxidant approaches
- Targeting NCOA4-mediated ferritinophagy
- GPX4 is a susceptibility gene for ALS
- Motor neurons show ferroptosis sensitivity
- Lipid peroxidation elevated in ALS patients
- Ferroptosis markers in ALS models
- GPX4 mutations: Cause familial ALS
- C9orf72: Related to system Xc⁻ dysfunction
- Lipid metabolism alterations: Affect membrane composition
- Axonal stress: Increases susceptibility
- Gene therapy for GPX4
- Antioxidant delivery
- Iron modulation
- Lipoxygenase inhibitors
- Iron accumulation in striatum
- Elevated lipid peroxidation
- GPX4 dysregulation
- Therapeutic potential for iron chelation
- Oligodendrocyte ferroptosis in demyelination
- Iron released from myelin breakdown
- Therapeutic implications for neuroprotection
- Post-ischemic ferroptosis contributes to damage
- Iron chelation reduces infarct size
- Combined approaches with thrombolysis
| Marker |
Detection Method |
Significance |
| 4-HNE |
Immunohistochemistry |
Lipid peroxidation product |
| MDA |
Biochemical assay |
Lipid peroxidation marker |
| Ptgs2 (COX-2) |
qPCR |
Ferroptosis marker gene |
| FSP1 |
Western blot |
Ferroptosis inhibitor |
| NCOA4 |
qPCR/Western |
Ferritinophagy regulator |
- MRI for brain iron quantification
- PET tracers for oxidative stress
- Advanced MRI techniques for lipid peroxidation
flowchart LR
A[Ferroptosis<br/>Inhibition] --> B[Iron Chelation]
A --> C[Antioxidants]
A --> D[GPX4 Activation]
A --> E[Lipid Metabolism<br/>Modulation]
B --> B1[Deferoxamine<br/>Clioquinol<br/>Deferasirox]
C --> C1[Ferrostatin-1<br/>Liproxstatin-1<br/>Vitamin E]
D --> D1[GPX4 Agonists<br/>GSH Precursors]
E --> E1[ACSL4 Inhibitors<br/>LOX Inhibitors]
- Iron chelation: Deferoxamine, clioquinol (in trials for AD/PD)
- Antioxidants: Vitamin E, CoQ10 (some clinical evidence)
- Lipid-lowering agents: May affect PUFA metabolism
- Gene therapy: GPX4 delivery, NCOA4 modulation
- Blood-brain barrier penetration
- Specificity of interventions
- Timing of intervention
- Biomarker development
- System biology approaches: Multi-omics integration
- Single-cell analysis: Cell-type specific ferroptosis
- Spatiotemporal dynamics: When and where ferroptosis occurs
- Synthetic lethality: Combination therapies
- Is ferroptosis a primary death mechanism or secondary process?
- Can ferroptosis be selectively induced in disease states?
- What determines cell-type susceptibility?
- How does ferroptosis interact with other cell death pathways?
The study of Ferroptosis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Dixon et al., Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death (2012)
- Stockwell et al., Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease (2017)
- Weiland et al., Ferroptosis in Neuronal Cell Death and Neurodegeneration (2019)
- Bao et al., Ferroptosis in Alzheimer's Disease: From pathogenesis to therapeutic potential (2021)
- Maher et al., Targeting Ferroptosis to treat Parkinson's Disease (2020)
- Wang et al., GPX4 in Neurodegeneration: A protective shield against ferroptosis (2022)
- Li et al., Ferroptosis in Amyotrophic Lateral Sclerosis: Pathogenesis and therapeutic targets (2021)
- Masaldan et al., Iron accumulation in senescence and neurodegeneration (2019)